Matteo Aldo Bonizzoni

Matteo Aldo Bonizzoni

Auto-generated profile, based on publicly available information

Matteo Aldo Bonizzoni

Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
ABAlessandro Belletti
Alessandro Belletti
OPOttavia Pallanch
Ottavia Pallanch
MBMatteo Aldo Bonizzoni
Matteo Aldo Bonizzoni
LGLeonardo Guidi
Leonardo Guidi
FCFrancesco De Cobelli
Francesco De Cobelli
DPDiego Palumbo
Diego Palumbo

27 May 2024 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
SSStefano Salvati
Stefano Salvati
JUJacopo D’Andria Ursoleo
Jacopo D’Andria Ursoleo
ABAlessandro Belletti
Alessandro Belletti
GMGiacomo Monti
Giacomo Monti
MBMatteo Aldo Bonizzoni
Matteo Aldo Bonizzoni
GLGiovanni Landoni
Giovanni Landoni

5 September 2023 in Blood Purification
Verified
Journal Article
Closed access
PDF file
MPMarina Pieri
Marina Pieri
MBMatteo A. Bonizzoni
Matteo A. Bonizzoni
ABAlessandro Belletti
Alessandro Belletti
MCMaria G. Calabrò
Maria G. Calabrò
EFEvgeny Fominskiy
Evgeny Fominskiy
ASAnna M. Scandroglio
Anna M. Scandroglio
Introduction: Critically ill patients with inflammatory dysregulation and organ disfunction may benefit from blood purification, although the use of this technique has not been described in large case series. We evaluated clinical outcomes and survival in high-risk intensive care unit (ICU) patients who underwent extracorporeal blood purification. Methods: 359 consecutive ICU patients treated with CytoSorb were included. Results: Main admission diagnoses were 120 (34%) refractory cardiac arrest under mechanical chest compression; 101 (28%) profound cardiogenic shock; 81 (23%) post-cardiotomy cardiogenic shock; and 37 (10%) respiratory failure. Fifteen patients (4%) were positive for SARS-CoV-2 infection. We observed 49% 30-day mortality, 57% ICU mortality, and 62% hospital mortality, all lower than the 71% mortality predicted by SAPS II and 68% predicted by SOFA score. Parameters of shock and organ failure, above all vasoactive inotropic score, reduced during CytoSorb treatment. Multivariable analysis identified SAPS II, lactate dehydrogenase, ICU stay duration, vasoactive inotropic score, lactates, intra-aortic counterpulsation on top of VA-ECMO, and total bilirubin as predictors of mortality. No CytoSorb-related complications occurred. Conclusion: CytoSorb treatment was effective in reducing laboratory parameters of shock and vasoactive inotropic score with possible survival implications in a large population of critically ill patients.

24 February 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
GLGiovanni Landoni
Giovanni Landoni
AOAlessandro Oriani
Alessandro Oriani
LTLian Kah Ti
Lian Kah Ti
Rosario LosiggioRosario Losiggio
Rosario Losiggio
NBNikola Bradic
Nikola Bradic
FMFabrizio Monaco
Fabrizio Monaco

19 January 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
APAlessandro Pruna
Alessandro Pruna
AOAlessandro Oriani
Alessandro Oriani
FMFabrizio Monaco
Fabrizio Monaco
GLGiovanni Landoni
Giovanni Landoni
MBMatteo Aldo Bonizzoni
Matteo Aldo Bonizzoni
NBNazar A. Bukamal
Nazar A. Bukamal